Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Exelixis share price today

Exelixis, Inc. · EXEL · Healthcare · Biotechnology · price as of the 4 November 2026 close, updated every trading day · results updated weekly · All US stock lists

Exelixis share price: $72.75 at the close on 4 November 2026, +78.3% in a year.

Growing steadilyBusiness trend from the last 12 quarters
$72.75Price +78.3% in a year
21.7×P/E higher than 54% of the last 4.6 years
$629 MRevenue (Jun 2026) +10.6% on a year ago
$212 MProfit (Jun 2026) +14.7% on a year ago
39.5%Operating margin +1.9 points on a year ago
36%ROE FY25
73.3%ROIC against a 6.5% cost of capital: +66.8 points

Exelixis, Inc. is reporting record margins.

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high.

The price has been rising for 32 weeks, and the P/E is higher than 54% of its own last 4.6 years. Over the last four quarters, results have been improving, with profit +14.7% on a year earlier, and 127% of the last 3 years' profit came in as cash. What will decide it: the next one or two quarters of results.

What is the Exelixis share price today?

Exelixis, Inc.'s share price was $72.75 at the close on 4 November 2026. It has been rising for 32 weeks. That is 41.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $41 and $73, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Exelixis, Inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 12 weeks in a row.

1Y

Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.

  • Price $72.75
  • 50-day avg $60.38
  • 200-day avg $51.32
Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.
WeekPrice50-day avg200-day avg
31 Oct 2025$38.67$38.83$38.85
7 Nov 2025$40.81$38.97$38.95
14 Nov 2025$41.65$39.47$39.20
21 Nov 2025$42.51$39.86$39.42
28 Nov 2025$44.17$40.16$39.63
5 Dec 2025$44.36$40.61$39.86
12 Dec 2025$40.88$40.69$39.96
19 Dec 2025$44.30$40.98$40.06
26 Dec 2025$46.24$41.57$40.23
2 Jan 2026$43.58$42.13$40.38
9 Jan 2026$44.04$42.68$40.55
16 Jan 2026$43.96$43.27$40.74
23 Jan 2026$44.27$43.55$40.91
30 Jan 2026$41.36$43.57$41.11
6 Feb 2026$43.90$43.63$41.27
13 Feb 2026$43.92$43.59$41.41
20 Feb 2026$43.63$43.62$41.51
27 Feb 2026$44.06$43.93$41.70
6 Mar 2026$41.55$43.72$41.64
13 Mar 2026$41.24$43.30$41.60
20 Mar 2026$41.27$43.04$41.57
27 Mar 2026$41.53$42.80$41.55
2 Apr 2026$43.88$42.70$41.58
10 Apr 2026$44.27$42.76$41.63
17 Apr 2026$44.89$43.02$41.66
24 Apr 2026$44.94$43.24$41.69
1 May 2026$43.68$43.30$41.68
8 May 2026$48.16$43.50$41.72
15 May 2026$50.13$44.36$41.94
22 May 2026$50.15$45.16$42.25
29 May 2026$50.48$45.89$42.51
5 Jun 2026$52.70$46.83$42.83
12 Jun 2026$53.13$47.86$43.20
18 Jun 2026$51.91$48.53$43.49
26 Jun 2026$54.77$49.30$43.86
2 Jul 2026$55.85$50.10$44.18
10 Jul 2026$56.50$51.19$44.60
17 Jul 2026$55.92$52.34$45.01
24 Jul 2026$55.37$53.05$45.37
31 Jul 2026$53.03$53.57$45.79
7 Aug 2026$54.07$54.05$46.20
14 Aug 2026$51.24$54.14$46.53
21 Aug 2026$54.08$54.24$46.90
28 Aug 2026$54.45$54.50$47.28
4 Sep 2026$59.01$55.05$47.65
11 Sep 2026$56.12$55.29$47.95
18 Sep 2026$58.36$55.39$48.30
25 Sep 2026$58.16$55.56$48.65
2 Oct 2026$58.39$55.83$49.08
9 Oct 2026$59.86$56.14$49.47
16 Oct 2026$62.23$56.79$49.85
23 Oct 2026$64.53$58.04$50.36
30 Oct 2026$69.39$59.39$50.91
4 Nov 2026$72.75$60.38$51.32
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 1-year window.

3Y

Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.

  • Price $72.75
  • 50-day avg $60.38
  • 200-day avg $51.32
Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.
WeekPrice50-day avg200-day avg
3 Nov 2023$21.00$21.55$19.60
10 Nov 2023$21.00$21.41$19.69
17 Nov 2023$21.13$21.30$19.78
24 Nov 2023$21.68$21.24$19.86
1 Dec 2023$21.94$21.24$19.95
8 Dec 2023$22.00$21.25$20.07
15 Dec 2023$23.41$21.35$20.21
22 Dec 2023$23.94$21.55$20.39
29 Dec 2023$23.99$21.75$20.52
5 Jan 2024$23.24$22.03$20.63
12 Jan 2024$22.70$22.26$20.74
19 Jan 2024$22.48$22.40$20.81
26 Jan 2024$22.12$22.54$20.86
2 Feb 2024$21.49$22.60$20.92
9 Feb 2024$20.22$22.53$20.96
16 Feb 2024$20.48$22.39$21.01
23 Feb 2024$21.53$22.30$21.04
1 Mar 2024$22.24$22.17$21.11
8 Mar 2024$22.21$22.03$21.18
15 Mar 2024$22.98$21.91$21.27
22 Mar 2024$23.78$21.96$21.37
28 Mar 2024$23.73$22.05$21.46
5 Apr 2024$23.14$22.16$21.58
12 Apr 2024$22.81$22.28$21.67
19 Apr 2024$22.52$22.42$21.76
26 Apr 2024$23.70$22.73$21.87
3 May 2024$21.90$22.93$21.95
10 May 2024$21.37$22.93$22.00
17 May 2024$20.91$22.81$22.03
24 May 2024$20.57$22.63$22.04
31 May 2024$21.69$22.43$22.02
7 Jun 2024$21.88$22.25$22.04
14 Jun 2024$21.74$22.08$22.04
21 Jun 2024$22.20$21.95$22.03
28 Jun 2024$22.47$21.91$22.03
5 Jul 2024$22.10$21.86$22.04
12 Jul 2024$22.40$21.72$22.06
19 Jul 2024$22.60$21.78$22.07
26 Jul 2024$23.39$21.92$22.09
2 Aug 2024$24.17$22.18$22.14
9 Aug 2024$26.97$22.67$22.26
16 Aug 2024$26.35$23.16$22.42
23 Aug 2024$25.88$23.58$22.56
30 Aug 2024$26.03$23.99$22.68
6 Sep 2024$25.15$24.25$22.77
13 Sep 2024$26.46$24.65$22.89
20 Sep 2024$26.42$25.13$23.02
27 Sep 2024$25.96$25.49$23.13
4 Oct 2024$26.66$25.87$23.20
11 Oct 2024$26.23$26.10$23.26
18 Oct 2024$28.90$26.44$23.37
25 Oct 2024$27.87$26.61$23.50
1 Nov 2024$34.12$27.12$23.72
8 Nov 2024$36.25$28.07$24.04
15 Nov 2024$34.45$29.04$24.38
22 Nov 2024$35.61$29.90$24.73
29 Nov 2024$36.46$30.63$25.05
6 Dec 2024$35.82$31.57$25.42
13 Dec 2024$35.03$32.47$25.76
20 Dec 2024$33.29$33.31$26.06
27 Dec 2024$33.81$33.81$26.28
3 Jan 2025$33.97$34.20$26.49
10 Jan 2025$36.02$34.70$26.71
17 Jan 2025$36.20$35.06$27.02
24 Jan 2025$32.38$34.93$27.23
31 Jan 2025$33.15$34.69$27.48
7 Feb 2025$33.48$34.54$27.74
14 Feb 2025$35.00$34.30$28.00
21 Feb 2025$36.85$34.26$28.25
28 Feb 2025$38.69$34.50$28.65
7 Mar 2025$38.58$34.92$29.08
14 Mar 2025$36.65$35.27$29.50
21 Mar 2025$36.96$35.59$29.89
28 Mar 2025$36.70$35.74$30.27
4 Apr 2025$34.57$35.85$30.63
11 Apr 2025$35.31$36.06$30.95
17 Apr 2025$36.19$36.30$31.23
25 Apr 2025$37.43$36.64$31.59
2 May 2025$39.60$37.06$32.01
9 May 2025$36.17$37.06$32.37
16 May 2025$45.40$37.41$32.85
23 May 2025$42.39$38.00$33.35
30 May 2025$43.04$38.48$33.66
6 Jun 2025$43.03$39.01$34.07
13 Jun 2025$41.59$39.54$34.47
20 Jun 2025$40.37$40.02$34.77
27 Jun 2025$43.67$40.86$35.23
3 Jul 2025$46.15$41.54$35.59
11 Jul 2025$44.86$42.20$36.03
18 Jul 2025$44.47$42.79$36.49
25 Jul 2025$45.60$43.61$36.95
1 Aug 2025$37.26$42.94$37.27
8 Aug 2025$37.72$42.39$37.49
15 Aug 2025$38.31$41.94$37.74
22 Aug 2025$38.63$41.50$37.90
29 Aug 2025$37.42$41.16$37.97
5 Sep 2025$37.88$40.69$38.01
12 Sep 2025$39.15$40.15$38.10
19 Sep 2025$40.10$39.67$38.19
26 Sep 2025$39.04$39.11$38.28
3 Oct 2025$40.09$38.73$38.42
10 Oct 2025$38.15$38.63$38.54
17 Oct 2025$39.25$38.83$38.68
24 Oct 2025$38.72$38.70$38.75
31 Oct 2025$38.67$38.83$38.85
7 Nov 2025$40.81$38.97$38.95
14 Nov 2025$41.65$39.47$39.20
21 Nov 2025$42.51$39.86$39.42
28 Nov 2025$44.17$40.16$39.63
5 Dec 2025$44.36$40.61$39.86
12 Dec 2025$40.88$40.69$39.96
19 Dec 2025$44.30$40.98$40.06
26 Dec 2025$46.24$41.57$40.23
2 Jan 2026$43.58$42.13$40.38
9 Jan 2026$44.04$42.68$40.55
16 Jan 2026$43.96$43.27$40.74
23 Jan 2026$44.27$43.55$40.91
30 Jan 2026$41.36$43.57$41.11
6 Feb 2026$43.90$43.63$41.27
13 Feb 2026$43.92$43.59$41.41
20 Feb 2026$43.63$43.62$41.51
27 Feb 2026$44.06$43.93$41.70
6 Mar 2026$41.55$43.72$41.64
13 Mar 2026$41.24$43.30$41.60
20 Mar 2026$41.27$43.04$41.57
27 Mar 2026$41.53$42.80$41.55
2 Apr 2026$43.88$42.70$41.58
10 Apr 2026$44.27$42.76$41.63
17 Apr 2026$44.89$43.02$41.66
24 Apr 2026$44.94$43.24$41.69
1 May 2026$43.68$43.30$41.68
8 May 2026$48.16$43.50$41.72
15 May 2026$50.13$44.36$41.94
22 May 2026$50.15$45.16$42.25
29 May 2026$50.48$45.89$42.51
5 Jun 2026$52.70$46.83$42.83
12 Jun 2026$53.13$47.86$43.20
18 Jun 2026$51.91$48.53$43.49
26 Jun 2026$54.77$49.30$43.86
2 Jul 2026$55.85$50.10$44.18
10 Jul 2026$56.50$51.19$44.60
17 Jul 2026$55.92$52.34$45.01
24 Jul 2026$55.37$53.05$45.37
31 Jul 2026$53.03$53.57$45.79
7 Aug 2026$54.07$54.05$46.20
14 Aug 2026$51.24$54.14$46.53
21 Aug 2026$54.08$54.24$46.90
28 Aug 2026$54.45$54.50$47.28
4 Sep 2026$59.01$55.05$47.65
11 Sep 2026$56.12$55.29$47.95
18 Sep 2026$58.36$55.39$48.30
25 Sep 2026$58.16$55.56$48.65
2 Oct 2026$58.39$55.83$49.08
9 Oct 2026$59.86$56.14$49.47
16 Oct 2026$62.23$56.79$49.85
23 Oct 2026$64.53$58.04$50.36
30 Oct 2026$69.39$59.39$50.91
4 Nov 2026$72.75$60.38$51.32
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 3-year window.

5Y

Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.

  • Price $72.75
  • 50-day avg $60.38
  • 200-day avg $51.32
Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.
WeekPrice50-day avg200-day avg
29 Oct 2021$21.51$20.55$21.40
12 Nov 2021$18.10$20.57$21.23
26 Nov 2021$17.06$20.14$21.00
10 Dec 2021$16.65$19.34$20.72
23 Dec 2021$19.28$18.78$20.54
7 Jan 2022$18.74$18.20$20.32
21 Jan 2022$17.32$17.75$20.09
4 Feb 2022$18.79$17.81$19.80
18 Feb 2022$19.56$18.28$19.53
4 Mar 2022$20.70$18.77$19.33
18 Mar 2022$21.39$19.17$19.22
1 Apr 2022$22.89$19.98$19.19
14 Apr 2022$23.09$20.87$19.26
29 Apr 2022$22.34$21.62$19.50
13 May 2022$20.08$21.82$19.71
27 May 2022$18.40$21.38$19.78
10 Jun 2022$18.14$20.86$19.79
24 Jun 2022$22.22$20.20$19.77
8 Jul 2022$22.01$19.99$19.83
22 Jul 2022$20.86$19.88$19.86
5 Aug 2022$21.52$20.31$19.85
19 Aug 2022$19.33$20.53$19.76
2 Sep 2022$17.91$20.47$19.75
16 Sep 2022$17.15$19.74$19.76
30 Sep 2022$15.68$18.69$19.74
14 Oct 2022$15.65$17.60$19.59
28 Oct 2022$16.63$16.89$19.49
11 Nov 2022$16.80$16.50$19.44
25 Nov 2022$16.94$16.37$19.37
9 Dec 2022$15.77$16.44$19.25
23 Dec 2022$15.83$16.47$19.00
6 Jan 2023$17.27$16.46$18.81
20 Jan 2023$16.73$16.48$18.56
3 Feb 2023$17.55$16.62$18.29
17 Feb 2023$17.49$16.75$18.04
3 Mar 2023$17.15$16.98$17.89
17 Mar 2023$17.55$17.20$17.83
31 Mar 2023$19.41$17.60$17.83
14 Apr 2023$19.46$18.04$17.82
28 Apr 2023$18.30$18.29$17.69
12 May 2023$19.18$18.65$17.58
26 May 2023$19.13$19.14$17.50
9 Jun 2023$19.20$19.29$17.50
23 Jun 2023$19.86$19.21$17.55
7 Jul 2023$19.31$19.20$17.63
21 Jul 2023$19.69$19.30$17.78
4 Aug 2023$20.27$19.40$18.00
18 Aug 2023$21.10$19.76$18.23
1 Sep 2023$22.74$20.34$18.50
15 Sep 2023$21.81$20.86$18.74
29 Sep 2023$21.85$21.33$18.99
13 Oct 2023$21.36$21.70$19.29
27 Oct 2023$20.20$21.64$19.49
10 Nov 2023$21.00$21.41$19.69
24 Nov 2023$21.68$21.24$19.86
8 Dec 2023$22.00$21.25$20.07
22 Dec 2023$23.94$21.55$20.39
5 Jan 2024$23.24$22.03$20.63
19 Jan 2024$22.48$22.40$20.81
2 Feb 2024$21.49$22.60$20.92
16 Feb 2024$20.48$22.39$21.01
1 Mar 2024$22.24$22.17$21.11
15 Mar 2024$22.98$21.91$21.27
28 Mar 2024$23.73$22.05$21.46
12 Apr 2024$22.81$22.28$21.67
26 Apr 2024$23.70$22.73$21.87
10 May 2024$21.37$22.93$22.00
24 May 2024$20.57$22.63$22.04
7 Jun 2024$21.88$22.25$22.04
21 Jun 2024$22.20$21.95$22.03
5 Jul 2024$22.10$21.86$22.04
19 Jul 2024$22.60$21.78$22.07
2 Aug 2024$24.17$22.18$22.14
16 Aug 2024$26.35$23.16$22.42
30 Aug 2024$26.03$23.99$22.68
13 Sep 2024$26.46$24.65$22.89
27 Sep 2024$25.96$25.49$23.13
11 Oct 2024$26.23$26.10$23.26
25 Oct 2024$27.87$26.61$23.50
8 Nov 2024$36.25$28.07$24.04
22 Nov 2024$35.61$29.90$24.73
6 Dec 2024$35.82$31.57$25.42
20 Dec 2024$33.29$33.31$26.06
3 Jan 2025$33.97$34.20$26.49
17 Jan 2025$36.20$35.06$27.02
31 Jan 2025$33.15$34.69$27.48
14 Feb 2025$35.00$34.30$28.00
28 Feb 2025$38.69$34.50$28.65
14 Mar 2025$36.65$35.27$29.50
28 Mar 2025$36.70$35.74$30.27
11 Apr 2025$35.31$36.06$30.95
25 Apr 2025$37.43$36.64$31.59
9 May 2025$36.17$37.06$32.37
23 May 2025$42.39$38.00$33.35
6 Jun 2025$43.03$39.01$34.07
20 Jun 2025$40.37$40.02$34.77
3 Jul 2025$46.15$41.54$35.59
18 Jul 2025$44.47$42.79$36.49
1 Aug 2025$37.26$42.94$37.27
15 Aug 2025$38.31$41.94$37.74
29 Aug 2025$37.42$41.16$37.97
12 Sep 2025$39.15$40.15$38.10
26 Sep 2025$39.04$39.11$38.28
10 Oct 2025$38.15$38.63$38.54
24 Oct 2025$38.72$38.70$38.75
7 Nov 2025$40.81$38.97$38.95
21 Nov 2025$42.51$39.86$39.42
5 Dec 2025$44.36$40.61$39.86
19 Dec 2025$44.30$40.98$40.06
2 Jan 2026$43.58$42.13$40.38
16 Jan 2026$43.96$43.27$40.74
30 Jan 2026$41.36$43.57$41.11
13 Feb 2026$43.92$43.59$41.41
27 Feb 2026$44.06$43.93$41.70
13 Mar 2026$41.24$43.30$41.60
27 Mar 2026$41.53$42.80$41.55
10 Apr 2026$44.27$42.76$41.63
24 Apr 2026$44.94$43.24$41.69
8 May 2026$48.16$43.50$41.72
22 May 2026$50.15$45.16$42.25
5 Jun 2026$52.70$46.83$42.83
18 Jun 2026$51.91$48.53$43.49
2 Jul 2026$55.85$50.10$44.18
17 Jul 2026$55.92$52.34$45.01
31 Jul 2026$53.03$53.57$45.79
14 Aug 2026$51.24$54.14$46.53
28 Aug 2026$54.45$54.50$47.28
11 Sep 2026$56.12$55.29$47.95
25 Sep 2026$58.16$55.56$48.65
9 Oct 2026$59.86$56.14$49.47
23 Oct 2026$64.53$58.04$50.36
4 Nov 2026$72.75$60.38$51.32
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 5-year window.

10Y

Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.

  • Price $72.75
  • 50-day avg $60.38
  • 200-day avg $51.32
Nov 2026: $72.75, 41.8% above its 200-day average. The price has been rising for 32 weeks.
WeekPrice50-day avg200-day avg
28 Oct 2016$10.88$12.31–
18 Nov 2016$16.96$13.09–
9 Dec 2016$16.84$13.98–
30 Dec 2016$14.91$14.99–
20 Jan 2017$17.92$16.55–
10 Feb 2017$22.08$17.54–
3 Mar 2017$23.08$19.06–
24 Mar 2017$20.91$20.78–
13 Apr 2017$21.29$21.53–
5 May 2017$21.69$21.60$16.35
26 May 2017$19.35$21.18$17.19
16 Jun 2017$19.26$20.65$17.77
7 Jul 2017$25.21$21.49$18.58
28 Jul 2017$27.63$22.96$19.58
18 Aug 2017$26.33$25.14$20.72
8 Sep 2017$25.97$26.71$21.62
29 Sep 2017$24.23$26.81$22.30
20 Oct 2017$27.17$26.53$23.09
10 Nov 2017$25.85$26.20$23.68
1 Dec 2017$28.12$25.85$24.07
22 Dec 2017$29.47$26.52$24.42
12 Jan 2018$30.38$27.56$25.02
2 Feb 2018$30.22$28.67$25.64
23 Feb 2018$29.51$29.31$26.13
16 Mar 2018$24.64$28.28$26.50
6 Apr 2018$21.09$26.29$26.70
27 Apr 2018$21.34$23.65$26.41
18 May 2018$21.58$21.87$25.97
8 Jun 2018$19.41$20.88$25.53
29 Jun 2018$21.52$20.56$24.98
20 Jul 2018$21.29$20.60$24.68
10 Aug 2018$20.40$20.74$24.28
31 Aug 2018$18.79$20.45$23.75
21 Sep 2018$16.76$19.41$23.12
12 Oct 2018$16.24$18.20$22.36
2 Nov 2018$17.41$16.91$21.26
23 Nov 2018$18.07$16.62$20.37
14 Dec 2018$21.03$17.56$19.82
4 Jan 2019$20.73$18.25$19.48
25 Jan 2019$23.27$20.34$19.54
15 Feb 2019$22.26$21.58$19.66
8 Mar 2019$23.04$22.19$19.75
29 Mar 2019$23.80$22.88$20.03
18 Apr 2019$20.90$23.07$20.26
10 May 2019$19.76$22.60$20.17
31 May 2019$19.59$21.51$20.09
21 Jun 2019$21.37$20.39$20.20
12 Jul 2019$20.98$20.35$20.47
2 Aug 2019$19.79$20.70$20.76
23 Aug 2019$20.05$20.92$21.15
13 Sep 2019$19.24$20.47$21.29
4 Oct 2019$17.04$19.70$21.14
25 Oct 2019$17.25$18.58$20.87
15 Nov 2019$16.51$17.33$20.35
6 Dec 2019$17.36$16.64$19.99
27 Dec 2019$18.13$16.92$19.64
17 Jan 2020$19.82$17.49$19.26
7 Feb 2020$19.02$18.11$18.95
28 Feb 2020$18.59$18.90$18.95
20 Mar 2020$15.15$18.56$18.74
9 Apr 2020$18.02$17.99$18.50
1 May 2020$24.10$19.14$18.64
22 May 2020$24.62$21.22$19.01
12 Jun 2020$22.39$23.27$19.20
2 Jul 2020$23.48$24.40$19.48
24 Jul 2020$24.59$23.88$19.94
14 Aug 2020$21.98$23.43$20.40
4 Sep 2020$20.67$23.08$20.84
25 Sep 2020$23.84$23.17$21.35
16 Oct 2020$23.23$23.11$21.78
6 Nov 2020$20.71$22.97$21.98
27 Nov 2020$19.41$22.12$22.06
18 Dec 2020$19.95$20.67$22.04
8 Jan 2021$22.82$20.17$22.36
29 Jan 2021$22.21$20.77$22.75
19 Feb 2021$22.21$21.79$22.61
12 Mar 2021$23.28$22.42$22.36
1 Apr 2021$23.12$22.49$22.34
23 Apr 2021$24.73$22.85$22.37
14 May 2021$25.56$23.64$22.38
4 Jun 2021$22.37$23.74$22.43
25 Jun 2021$23.42$23.62$22.50
16 Jul 2021$16.80$21.79$22.04
6 Aug 2021$17.25$19.56$21.53
27 Aug 2021$19.43$18.32$21.30
17 Sep 2021$20.72$18.26$21.34
8 Oct 2021$21.62$19.37$21.42
29 Oct 2021$21.51$20.55$21.40
19 Nov 2021$18.03$20.38$21.11
10 Dec 2021$16.65$19.34$20.72
31 Dec 2021$18.28$18.49$20.43
21 Jan 2022$17.32$17.75$20.09
11 Feb 2022$18.75$18.02$19.66
4 Mar 2022$20.70$18.77$19.33
25 Mar 2022$21.88$19.49$19.19
14 Apr 2022$23.09$20.87$19.26
6 May 2022$21.49$21.92$19.64
27 May 2022$18.40$21.38$19.78
17 Jun 2022$18.56$20.36$19.75
8 Jul 2022$22.01$19.99$19.83
29 Jul 2022$20.92$19.98$19.85
19 Aug 2022$19.33$20.53$19.76
9 Sep 2022$17.90$20.16$19.75
30 Sep 2022$15.68$18.69$19.74
21 Oct 2022$16.45$17.18$19.54
11 Nov 2022$16.80$16.50$19.44
2 Dec 2022$17.39$16.39$19.32
23 Dec 2022$15.83$16.47$19.00
13 Jan 2023$16.43$16.49$18.69
3 Feb 2023$17.55$16.62$18.29
24 Feb 2023$17.13$16.84$17.96
17 Mar 2023$17.55$17.20$17.83
6 Apr 2023$20.48$17.82$17.86
28 Apr 2023$18.30$18.29$17.69
19 May 2023$19.79$18.94$17.54
9 Jun 2023$19.20$19.29$17.50
30 Jun 2023$19.11$19.18$17.58
21 Jul 2023$19.69$19.30$17.78
11 Aug 2023$21.52$19.57$18.11
1 Sep 2023$22.74$20.34$18.50
22 Sep 2023$21.48$21.08$18.85
13 Oct 2023$21.36$21.70$19.29
3 Nov 2023$21.00$21.55$19.60
24 Nov 2023$21.68$21.24$19.86
15 Dec 2023$23.41$21.35$20.21
5 Jan 2024$23.24$22.03$20.63
26 Jan 2024$22.12$22.54$20.86
16 Feb 2024$20.48$22.39$21.01
8 Mar 2024$22.21$22.03$21.18
28 Mar 2024$23.73$22.05$21.46
19 Apr 2024$22.52$22.42$21.76
10 May 2024$21.37$22.93$22.00
31 May 2024$21.69$22.43$22.02
21 Jun 2024$22.20$21.95$22.03
12 Jul 2024$22.40$21.72$22.06
2 Aug 2024$24.17$22.18$22.14
23 Aug 2024$25.88$23.58$22.56
13 Sep 2024$26.46$24.65$22.89
4 Oct 2024$26.66$25.87$23.20
25 Oct 2024$27.87$26.61$23.50
15 Nov 2024$34.45$29.04$24.38
6 Dec 2024$35.82$31.57$25.42
27 Dec 2024$33.81$33.81$26.28
17 Jan 2025$36.20$35.06$27.02
7 Feb 2025$33.48$34.54$27.74
28 Feb 2025$38.69$34.50$28.65
21 Mar 2025$36.96$35.59$29.89
11 Apr 2025$35.31$36.06$30.95
2 May 2025$39.60$37.06$32.01
23 May 2025$42.39$38.00$33.35
13 Jun 2025$41.59$39.54$34.47
3 Jul 2025$46.15$41.54$35.59
25 Jul 2025$45.60$43.61$36.95
15 Aug 2025$38.31$41.94$37.74
5 Sep 2025$37.88$40.69$38.01
26 Sep 2025$39.04$39.11$38.28
17 Oct 2025$39.25$38.83$38.68
7 Nov 2025$40.81$38.97$38.95
28 Nov 2025$44.17$40.16$39.63
19 Dec 2025$44.30$40.98$40.06
9 Jan 2026$44.04$42.68$40.55
30 Jan 2026$41.36$43.57$41.11
20 Feb 2026$43.63$43.62$41.51
13 Mar 2026$41.24$43.30$41.60
2 Apr 2026$43.88$42.70$41.58
24 Apr 2026$44.94$43.24$41.69
15 May 2026$50.13$44.36$41.94
5 Jun 2026$52.70$46.83$42.83
26 Jun 2026$54.77$49.30$43.86
17 Jul 2026$55.92$52.34$45.01
7 Aug 2026$54.07$54.05$46.20
28 Aug 2026$54.45$54.50$47.28
18 Sep 2026$58.36$55.39$48.30
9 Oct 2026$59.86$56.14$49.47
30 Oct 2026$69.39$59.39$50.91
4 Nov 2026$72.75$60.38$51.32
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 10-year window.

Price stage: Rising from Oct 2025 to Feb 2026; Sideways in Mar 2026; Rising from Apr 2026 to Nov 2026.

Price stage: Rising from Nov 2023 to Apr 2024; Sideways from May 2024 to Jun 2024; Rising from Jun 2024 to Feb 2026; Sideways in Mar 2026; Rising from Apr 2026 to Nov 2026.

Price stage: Falling from Oct 2021 to Feb 2022; Sideways from Feb 2022 to Aug 2022; Sideways from Sep 2022 to Nov 2022; Falling from Dec 2022 to Mar 2023; Sideways from Mar 2023 to Aug 2023; Rising from Sep 2023 to Apr 2024; Sideways from May 2024 to Jun 2024; Rising from Jun 2024 to Nov 2026.

Price stage: Rising from Dec 2017 to Feb 2018; Sideways from Mar 2018 to Jul 2018; Falling from Aug 2018 to Nov 2018; Sideways from Dec 2018 to Jul 2019; Sideways from Aug 2019 to Feb 2020; Falling from Feb 2020 to Apr 2020; Sideways from May 2020 to Oct 2020; Sideways from Nov 2020 to Feb 2021; Rising from Mar 2021 to Jul 2021; Falling from Aug 2021 to Feb 2022; Sideways from Mar 2022 to Aug 2022; Sideways from Sep 2022 to Nov 2022; Falling from Dec 2022 to Mar 2023; Sideways from Apr 2023 to Aug 2023; Rising from Sep 2023 to Nov 2026.

Week by week since 2016: did it beat the S&P 500 over the past 13 weeks?

Ahead in 276 of 527 weeks

Week by week since 2016: did it beat the S&P 500 over the past 13 weeks?
Week13-week return vs S&P 500
8 Jul 2016no S&P 500 reading
15 Jul 2016no S&P 500 reading
22 Jul 2016no S&P 500 reading
29 Jul 2016no S&P 500 reading
5 Aug 2016no S&P 500 reading
12 Aug 2016no S&P 500 reading
19 Aug 2016no S&P 500 reading
26 Aug 2016no S&P 500 reading
2 Sep 2016no S&P 500 reading
9 Sep 2016no S&P 500 reading
16 Sep 2016no S&P 500 reading
23 Sep 2016no S&P 500 reading
30 Sep 2016no S&P 500 reading
7 Oct 2016+57.8%
14 Oct 2016+35.4%
21 Oct 2016+34.7%
28 Oct 2016+20.6%
4 Nov 2016+11.0%
11 Nov 2016+54.8%
18 Nov 2016+54.2%
25 Nov 2016+53.2%
2 Dec 2016+49.9%
9 Dec 2016+34.4%
16 Dec 2016+18.4%
23 Dec 2016−1.0%
30 Dec 2016+13.2%
6 Jan 2017+12.6%
13 Jan 2017+57.0%
20 Jan 2017+49.1%
27 Jan 2017+62.9%
3 Feb 2017+60.1%
10 Feb 2017+27.7%
17 Feb 2017+28.7%
24 Feb 2017+20.7%
3 Mar 2017+24.3%
10 Mar 2017+23.6%
17 Mar 2017+25.9%
24 Mar 2017+32.1%
31 Mar 2017+39.9%
7 Apr 2017+30.1%
13 Apr 2017+12.6%
21 Apr 2017+13.6%
28 Apr 2017+16.6%
5 May 2017+2.5%
12 May 2017−5.4%
19 May 2017−16.2%
26 May 2017−12.9%
2 Jun 2017−19.9%
9 Jun 2017−13.5%
16 Jun 2017−14.9%
23 Jun 2017+9.8%
30 Jun 2017+11.1%
7 Jul 2017+20.2%
14 Jul 2017+20.0%
21 Jul 2017+24.6%
28 Jul 2017+19.6%
4 Aug 2017+19.7%
11 Aug 2017+20.5%
18 Aug 2017+31.9%
25 Aug 2017+39.2%
1 Sep 2017+50.7%
8 Sep 2017+33.6%
15 Sep 2017+40.4%
22 Sep 2017+0.3%
29 Sep 2017−5.5%
6 Oct 2017−3.1%
13 Oct 2017−11.2%
20 Oct 2017−4.4%
27 Oct 2017−8.0%
3 Nov 2017−6.0%
10 Nov 2017−8.2%
17 Nov 2017−6.1%
24 Nov 2017−11.3%
1 Dec 2017−9.7%
8 Dec 2017−3.3%
15 Dec 2017−12.3%
22 Dec 2017+13.2%
29 Dec 2017+19.2%
5 Jan 2018+15.5%
12 Jan 2018+13.7%
19 Jan 2018−6.0%
26 Jan 2018+2.5%
2 Feb 2018+8.5%
9 Feb 2018+7.8%
16 Feb 2018+4.7%
23 Feb 2018+8.6%
2 Mar 2018−16.1%
9 Mar 2018−14.5%
16 Mar 2018−8.5%
23 Mar 2018−19.4%
29 Mar 2018−25.7%
6 Apr 2018−28.3%
13 Apr 2018−28.1%
20 Apr 2018−20.5%
27 Apr 2018−22.5%
4 May 2018−22.3%
11 May 2018−35.0%
18 May 2018−25.4%
25 May 2018−28.4%
1 Jun 2018−16.2%
8 Jun 2018−20.6%
15 Jun 2018−21.4%
22 Jun 2018−18.2%
29 Jun 2018−5.9%
6 Jul 2018−5.5%
13 Jul 2018+1.5%
20 Jul 2018−2.9%
27 Jul 2018−4.1%
3 Aug 2018−14.8%
10 Aug 2018+0.6%
17 Aug 2018−16.1%
24 Aug 2018−21.0%
31 Aug 2018−14.8%
7 Sep 2018−7.8%
14 Sep 2018−18.6%
21 Sep 2018−22.6%
28 Sep 2018−24.8%
5 Oct 2018−21.4%
12 Oct 2018−24.4%
19 Oct 2018−22.4%
26 Oct 2018−27.9%
2 Nov 2018−11.4%
9 Nov 2018−16.4%
16 Nov 2018−2.7%
23 Nov 2018+10.9%
30 Nov 2018+13.1%
7 Dec 2018+19.1%
14 Dec 2018+34.4%
21 Dec 2018+23.3%
28 Dec 2018+24.5%
4 Jan 2019+30.0%
11 Jan 2019+52.5%
18 Jan 2019+42.8%
25 Jan 2019+61.7%
1 Feb 2019+36.2%
8 Feb 2019+30.2%
15 Feb 2019+22.9%
22 Feb 2019+13.1%
1 Mar 2019+11.0%
8 Mar 2019+8.0%
15 Mar 2019+8.6%
22 Mar 2019+15.0%
29 Mar 2019+8.4%
5 Apr 2019+4.2%
12 Apr 2019−14.4%
18 Apr 2019−16.6%
26 Apr 2019−22.1%
3 May 2019−20.8%
10 May 2019−13.6%
17 May 2019−16.2%
24 May 2019−6.7%
31 May 2019−12.6%
7 Jun 2019−17.1%
14 Jun 2019−22.5%
21 Jun 2019−13.2%
28 Jun 2019−13.9%
5 Jul 2019−17.5%
12 Jul 2019−13.2%
19 Jul 2019−0.7%
26 Jul 2019−1.7%
2 Aug 2019−4.3%
9 Aug 2019+3.2%
16 Aug 2019+11.3%
23 Aug 2019−2.3%
30 Aug 2019−4.9%
6 Sep 2019−8.2%
13 Sep 2019−6.4%
20 Sep 2019−9.9%
27 Sep 2019−16.6%
4 Oct 2019−17.9%
11 Oct 2019−19.8%
18 Oct 2019−23.1%
25 Oct 2019−16.9%
1 Nov 2019−23.7%
8 Nov 2019−29.5%
15 Nov 2019−31.9%
22 Nov 2019−28.0%
29 Nov 2019−23.7%
6 Dec 2019−15.6%
13 Dec 2019−12.8%
20 Dec 2019−12.9%
27 Dec 2019−8.6%
3 Jan 2020−9.7%
10 Jan 2020+1.0%
17 Jan 2020+9.3%
24 Jan 2020−4.5%
31 Jan 2020+2.3%
7 Feb 2020+13.1%
14 Feb 2020+17.5%
21 Feb 2020+22.3%
28 Feb 2020+17.5%
6 Mar 2020+13.0%
13 Mar 2020+9.2%
20 Mar 2020+10.5%
27 Mar 2020+16.5%
3 Apr 2020+20.1%
9 Apr 2020+12.9%
17 Apr 2020+11.7%
24 Apr 2020+61.2%
1 May 2020+52.2%
8 May 2020+48.7%
15 May 2020+39.2%
22 May 2020+28.1%
29 May 2020+30.2%
5 Jun 2020+12.6%
12 Jun 2020+20.6%
19 Jun 2020+24.7%
26 Jun 2020+14.4%
2 Jul 2020+16.3%
10 Jul 2020+24.2%
17 Jul 2020+14.3%
24 Jul 2020−20.7%
31 Jul 2020−19.7%
7 Aug 2020−28.4%
14 Aug 2020−32.3%
21 Aug 2020−24.5%
28 Aug 2020−27.7%
4 Sep 2020−14.9%
11 Sep 2020−12.8%
18 Sep 2020+3.7%
25 Sep 2020−5.4%
2 Oct 2020−7.3%
9 Oct 2020−13.3%
16 Oct 2020−13.5%
23 Oct 2020−17.1%
30 Oct 2020−11.3%
6 Nov 2020−12.0%
13 Nov 2020−14.6%
20 Nov 2020−19.7%
27 Nov 2020−14.0%
4 Dec 2020−16.1%
11 Dec 2020−18.2%
18 Dec 2020−37.2%
24 Dec 2020−25.4%
31 Dec 2020−26.2%
8 Jan 2021−14.5%
15 Jan 2021−6.0%
22 Jan 2021−11.4%
29 Jan 2021−4.9%
5 Feb 2021+1.2%
12 Feb 2021−1.0%
19 Feb 2021+7.7%
26 Feb 2021+7.0%
5 Mar 2021+13.9%
12 Mar 2021+9.6%
19 Mar 2021+11.8%
26 Mar 2021+2.2%
1 Apr 2021+8.0%
9 Apr 2021−6.6%
16 Apr 2021−11.7%
23 Apr 2021+2.9%
30 Apr 2021−1.9%
7 May 2021−0.5%
14 May 2021+10.6%
21 May 2021+3.7%
28 May 2021−6.3%
4 Jun 2021−10.0%
11 Jun 2021−9.0%
18 Jun 2021−10.8%
25 Jun 2021−4.5%
2 Jul 2021−29.3%
9 Jul 2021−27.9%
16 Jul 2021−32.2%
23 Jul 2021−37.9%
30 Jul 2021−36.6%
6 Aug 2021−36.1%
13 Aug 2021−35.5%
20 Aug 2021−31.5%
27 Aug 2021−21.0%
3 Sep 2021−18.8%
10 Sep 2021−18.1%
17 Sep 2021−13.9%
24 Sep 2021−17.2%
1 Oct 2021+17.8%
8 Oct 2021+19.5%
15 Oct 2021+26.5%
22 Oct 2021+24.9%
29 Oct 2021+22.9%
5 Nov 2021+6.3%
12 Nov 2021−5.8%
19 Nov 2021−8.0%
26 Nov 2021−14.1%
3 Dec 2021−20.0%
10 Dec 2021−22.3%
17 Dec 2021−16.3%
23 Dec 2021−11.3%
31 Dec 2021−24.5%
7 Jan 2022−19.8%
14 Jan 2022−21.2%
21 Jan 2022−15.7%
28 Jan 2022−13.6%
4 Feb 2022+1.3%
11 Feb 2022+9.3%
18 Feb 2022+15.9%
25 Feb 2022+22.9%
4 Mar 2022+35.4%
11 Mar 2022+36.8%
18 Mar 2022+20.9%
25 Mar 2022+17.3%
1 Apr 2022+29.9%
8 Apr 2022+26.8%
14 Apr 2022+33.2%
22 Apr 2022+32.2%
29 Apr 2022+32.5%
6 May 2022+22.7%
13 May 2022+15.9%
20 May 2022+1.1%
27 May 2022−3.7%
3 Jun 2022−3.0%
10 Jun 2022−6.4%
17 Jun 2022+4.5%
24 Jun 2022+15.4%
1 Jul 2022+10.1%
8 Jul 2022+8.8%
15 Jul 2022+4.4%
22 Jul 2022+0.3%
29 Jul 2022−6.4%
5 Aug 2022−0.4%
12 Aug 2022−9.3%
19 Aug 2022+0.5%
26 Aug 2022+1.5%
2 Sep 2022−1.5%
9 Sep 2022−5.6%
16 Sep 2022−13.0%
23 Sep 2022−21.1%
30 Sep 2022−21.0%
7 Oct 2022−23.4%
14 Oct 2022−19.5%
21 Oct 2022−15.9%
28 Oct 2022−14.9%
4 Nov 2022−14.5%
11 Nov 2022−7.1%
18 Nov 2022−6.3%
25 Nov 2022−6.3%
2 Dec 2022−6.6%
9 Dec 2022−8.6%
16 Dec 2022−6.5%
23 Dec 2022−6.8%
30 Dec 2022−4.8%
6 Jan 2023+5.2%
13 Jan 2023−6.4%
20 Jan 2023−4.1%
27 Jan 2023+0.8%
3 Feb 2023−2.9%
10 Feb 2023+2.1%
17 Feb 2023+0.6%
24 Feb 2023+2.6%
3 Mar 2023−0.7%
10 Mar 2023+7.6%
17 Mar 2023+8.3%
24 Mar 2023+13.4%
31 Mar 2023+14.0%
6 Apr 2023+13.1%
14 Apr 2023+14.9%
21 Apr 2023+9.5%
28 Apr 2023+2.2%
5 May 2023+10.9%
12 May 2023+8.4%
19 May 2023+10.4%
26 May 2023+5.7%
2 Jun 2023+6.0%
9 Jun 2023+3.7%
16 Jun 2023−3.9%
23 Jun 2023−2.0%
30 Jun 2023−9.8%
7 Jul 2023−12.9%
14 Jul 2023−9.3%
21 Jul 2023−6.1%
28 Jul 2023−1.4%
4 Aug 2023−4.2%
11 Aug 2023+3.9%
18 Aug 2023+2.3%
25 Aug 2023+10.2%
1 Sep 2023+13.1%
8 Sep 2023+11.5%
15 Sep 2023+13.4%
22 Sep 2023+8.8%
29 Sep 2023+17.9%
6 Oct 2023+17.1%
13 Oct 2023+14.1%
20 Oct 2023+14.1%
27 Oct 2023+11.9%
3 Nov 2023+6.3%
10 Nov 2023−1.3%
17 Nov 2023−3.1%
24 Nov 2023−4.9%
1 Dec 2023−5.3%
8 Dec 2023−3.8%
15 Dec 2023+1.5%
22 Dec 2023+1.4%
29 Dec 2023−1.4%
5 Jan 2024−4.3%
12 Jan 2024−4.2%
19 Jan 2024−8.0%
26 Jan 2024−9.2%
2 Feb 2024−11.4%
9 Feb 2024−17.5%
16 Feb 2024−13.9%
23 Feb 2024−12.2%
1 Mar 2024−10.3%
8 Mar 2024−10.2%
15 Mar 2024−10.5%
22 Mar 2024−10.7%
28 Mar 2024−11.1%
5 Apr 2024−11.2%
12 Apr 2024−6.7%
19 Apr 2024−2.5%
26 Apr 2024+2.9%
3 May 2024−1.5%
10 May 2024+1.8%
17 May 2024−3.9%
24 May 2024−8.7%
31 May 2024−5.3%
7 Jun 2024−5.8%
14 Jun 2024−11.9%
21 Jun 2024−11.1%
28 Jun 2024−9.4%
5 Jul 2024−11.5%
12 Jul 2024−11.4%
19 Jul 2024−10.5%
26 Jul 2024−8.4%
2 Aug 2024+6.1%
9 Aug 2024+23.9%
16 Aug 2024+21.3%
23 Aug 2024+19.6%
30 Aug 2024+13.1%
6 Sep 2024+13.8%
13 Sep 2024+18.2%
20 Sep 2024+14.6%
27 Sep 2024+10.5%
4 Oct 2024+17.3%
11 Oct 2024+13.6%
18 Oct 2024+21.4%
25 Oct 2024+12.8%
1 Nov 2024+34.0%
8 Nov 2024+22.2%
15 Nov 2024+25.1%
22 Nov 2024+31.7%
29 Nov 2024+33.2%
6 Dec 2024+29.9%
13 Dec 2024+24.9%
20 Dec 2024+22.0%
27 Dec 2024+26.1%
3 Jan 2025+24.1%
10 Jan 2025+37.2%
17 Jan 2025+23.0%
24 Jan 2025+11.2%
31 Jan 2025−8.2%
7 Feb 2025−8.1%
14 Feb 2025−2.5%
21 Feb 2025+2.7%
28 Feb 2025+7.5%
7 Mar 2025+13.0%
14 Mar 2025+11.5%
21 Mar 2025+15.6%
28 Mar 2025+15.2%
4 Apr 2025+16.4%
11 Apr 2025+6.0%
17 Apr 2025+11.9%
25 Apr 2025+25.0%
2 May 2025+25.3%
9 May 2025+14.1%
16 May 2025+32.3%
23 May 2025+18.5%
30 May 2025+12.0%
6 Jun 2025+7.5%
13 Jun 2025+7.4%
20 Jun 2025+3.9%
27 Jun 2025+8.3%
3 Jul 2025+9.7%
11 Jul 2025+10.3%
18 Jul 2025+3.7%
25 Jul 2025+6.1%
1 Aug 2025−15.6%
8 Aug 2025−8.6%
15 Aug 2025−23.9%
22 Aug 2025−20.3%
29 Aug 2025−22.5%
5 Sep 2025−20.0%
12 Sep 2025−16.0%
19 Sep 2025−12.4%
26 Sep 2025−18.2%
3 Oct 2025−20.1%
10 Oct 2025−19.7%
17 Oct 2025−17.6%
24 Oct 2025−21.4%
31 Oct 2025−5.9%
7 Nov 2025+2.9%
14 Nov 2025+4.3%
21 Nov 2025+7.9%
28 Nov 2025+12.1%
5 Dec 2025+11.2%
12 Dec 2025+0.7%
19 Dec 2025+7.9%
26 Dec 2025+14.1%
2 Jan 2026+6.6%
9 Jan 2026+9.2%
16 Jan 2026+7.9%
23 Jan 2026+12.6%
30 Jan 2026+5.5%
6 Feb 2026+4.6%
13 Feb 2026+4.0%
20 Feb 2026−2.0%
27 Feb 2026−0.6%
6 Mar 2026−4.4%
13 Mar 2026+3.7%
20 Mar 2026−2.1%
27 Mar 2026−2.0%
2 Apr 2026+4.7%
10 Apr 2026+2.6%
17 Apr 2026−0.6%
24 Apr 2026−2.1%
1 May 2026+1.5%
8 May 2026+2.9%
15 May 2026+5.7%
22 May 2026+6.8%
29 May 2026+4.3%
5 Jun 2026+17.1%
12 Jun 2026+16.8%
18 Jun 2026+10.6%
26 Jun 2026+16.9%
2 Jul 2026+13.7%
10 Jul 2026+16.5%
17 Jul 2026+19.9%
24 Jul 2026+19.7%
31 Jul 2026+17.7%
7 Aug 2026+7.4%
14 Aug 2026−2.8%
21 Aug 2026+5.1%
28 Aug 2026+6.2%
4 Sep 2026+7.5%
11 Sep 2026+2.6%
18 Sep 2026+10.4%
25 Sep 2026+0.4%
2 Oct 2026+1.2%
9 Oct 2026+2.8%
16 Oct 2026+8.6%
23 Oct 2026+13.7%
30 Oct 2026+29.7%
4 Nov 2026+35.4%
Each bar is one week, from 2016 to now (527 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the S&P 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 10 years the share price moved +793% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What dividend does Exelixis pay?

Exelixis, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Which stock lists is Exelixis on?

Exelixis is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Is Exelixis profitable?

Exelixis, Inc. earned $212 M of net profit in the Jun 2026 quarter, +14.7% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY25 profit was $783 M. Over 4 years profit has grown 35.7% a year on average. That is 33.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned $194 M.

For the full year, FY25 profit was $783 M (+50.1% on the year before).

FY25 profit $783 M (+50.1% on the year before), 35.7% a year over 4 years

  • Net profit $783 M
FY25 profit $783 M (+50.1% on the year before), 35.7% a year over 4 years
QuarterNet profit
FY21$231 M
FY22$182 M
FY23$208 M
FY24$521 M
FY25$783 M

Growth on a year earlier

  • Growth on a year earlier 50.1%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY22−21.1%
FY2314%
FY24150.9%
FY2550.1%
Top: net profit each year, $ M. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Jun 2026: $212 M (+14.7% on a year earlier), the 5th quarter in a row of growth

  • Net profit (quarterly) $212 M
Jun 2026: $212 M (+14.7% on a year earlier), the 5th quarter in a row of growth
QuarterNet profit (quarterly)
Mar 2024$37.3 M
Jun 2024$226 M
Sep 2024$118 M
Dec 2024$140 M
Mar 2025$160 M
Apr 2025$160 M
Jun 2025$185 M
Sep 2025$194 M
Dec 2025$245 M
Mar 2026$210 M
Apr 2026$210 M
Jun 2026$212 M

Growth on a year earlier

  • Growth on a year earlier 14.7%
Growth on a year earlier
QuarterGrowth on a year earlier
Mar 2024−6.8%
Jun 2024178.5%
Sep 202411,232.7%
Dec 202463.5%
Mar 2025327.7%
Apr 2025327.7%
Jun 2025−18.3%
Sep 202564.1%
Dec 202574.8%
Mar 202631.9%
Apr 202631.9%
Jun 202614.7%
Top: net profit each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Why profit moved: revenue changed +10.6% on a year earlier and the margin moved +1.9 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +38.3% and revenue +9.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

How much revenue does Exelixis make, and is it growing?

Exelixis, Inc. reported $629 M of revenue in the Jun 2026 quarter, +10.6% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown 12.8% a year on average. The last full year, FY25, came in at $2.3 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $2.4 B.

FY25 revenue was $2.3 B, +7.0% on the year before.

FY25 revenue $2.3 B (+7.0% on the year before), 12.8% a year over 4 years

  • Revenue $2.3 B
FY25 revenue $2.3 B (+7.0% on the year before), 12.8% a year over 4 years
QuarterRevenue
FY21$1.4 B
FY22$1.6 B
FY23$1.8 B
FY24$2.2 B
FY25$2.3 B

Growth on a year earlier

  • Growth on a year earlier 7%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY2212.3%
FY2313.6%
FY2418.5%
FY257%
Top: revenue each year, $ B. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Jun 2026: $629 M (+10.6% on a year earlier), the 5th quarter in a row of growth

  • Revenue (quarterly) $629 M
Jun 2026: $629 M (+10.6% on a year earlier), the 5th quarter in a row of growth
QuarterRevenue (quarterly)
Mar 2024$425 M
Jun 2024$637 M
Sep 2024$540 M
Dec 2024$567 M
Mar 2025$555 M
Apr 2025$555 M
Jun 2025$568 M
Sep 2025$598 M
Dec 2025$599 M
Mar 2026$611 M
Apr 2026$611 M
Jun 2026$629 M

Growth on a year earlier

  • Growth on a year earlier 10.6%
Growth on a year earlier
QuarterGrowth on a year earlier
Mar 20244%
Jun 202435.6%
Sep 202414.3%
Dec 202418.2%
Mar 202530.6%
Apr 202530.6%
Jun 2025−10.8%
Sep 202510.8%
Dec 20255.6%
Mar 202610%
Apr 202610%
Jun 202610.6%
Top: revenue each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Recent pace: the last four quarters grew +9.1% on average, against 12.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +7.6%, against +6.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +25.8%, against +29.7% a year (rolling over).

How much of every $100 of sales does Exelixis keep?

Exelixis, Inc.'s operating margin was 39.5% in the Jun 2026 quarter, 1.9 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved −3.4 percentage points. Across 5 years it has been between 9.3% and 38.5%.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

The latest quarter is above every full year in that period.

Across 5 years it has been between 9.3% and 38.5%, and FY25's 38.5% is the highest of them.

Why the margin moved: operating margin changed −3.4 percentage points on the year while gross margin changed −0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

FY25: 38.5%, the highest in a range of 9.3% to 38.5% over 5 years

  • Operating margin 38.5%
FY25: 38.5%, the highest in a range of 9.3% to 38.5% over 5 years
QuarterOperating margin
FY2120%
FY2212.5%
FY239.3%
FY2431.8%
FY2538.5%

Change on the year before (points)

  • Change on the year before (points) +6.7 pts
Change on the year before (points)
QuarterChange on the year before (points)
FY21–
FY22−7.5 pts
FY23−3.2 pts
FY24+22.5 pts
FY25+6.7 pts
Operating margin each year, % (top). Below: change on the year before, in percentage points. 5-year window.

Jun 2026: operating margin 39.5% (+1.9 points on a year earlier)

  • Operating margin 39.5%
Jun 2026: operating margin 39.5% (+1.9 points on a year earlier)
QuarterOperating margin
Mar 202414.7%
Jun 202443.4%
Sep 202434.8%
Dec 202428.8%
Mar 202533.6%
Apr 202533.6%
Jun 202537.6%
Sep 202542.9%
Dec 202539.4%
Mar 202641.1%
Apr 202641.1%
Jun 202639.5%

Change on a year earlier (points)

  • Change on a year earlier (points) +1.9 pts
Change on a year earlier (points)
QuarterChange on a year earlier (points)
Mar 2024+7.6 pts
Jun 2024+26.8 pts
Sep 2024+38.5 pts
Dec 2024+11.7 pts
Mar 2025+18.9 pts
Apr 2025+18.9 pts
Jun 2025−5.8 pts
Sep 2025+8.1 pts
Dec 2025+10.6 pts
Mar 2026+7.5 pts
Apr 2026+7.5 pts
Jun 2026+1.9 pts
Top: quarterly operating margin, %. Below: change on the same quarter a year earlier, in percentage points. Last 12 quarters. Operating profit as a share of revenue, each quarter.

Is Exelixis' profit turning into cash?

Over the last 3 years, 127% of Exelixis, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $884 M of operating cash against $783 M of profit. After $8.4 M of spending on assets, $876 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

FY25: operating cash $884 M against profit $783 M; 127% of 3 years' profit came in as cash

  • Operating cash $884 M
  • Net profit $783 M
  • Free cash $876 M
FY25: operating cash $884 M against profit $783 M; 127% of 3 years' profit came in as cash
QuarterOperating cashNet profitFree cash
FY21$401 M$231 M$347 M
FY22$363 M$182 M$335 M
FY23$333 M$208 M$293 M
FY24$700 M$521 M$672 M
FY25$884 M$783 M$876 M
Operating cash flow and net profit each year, $ M. The line is free cash flow: operating cash minus spending on assets. 5-year window, yearly figures.

Jun 2026: operating cash $308 M = 145% of the quarter's profit

  • Operating cash (quarterly) $308 M
Jun 2026: operating cash $308 M = 145% of the quarter's profit
QuarterOperating cash (quarterly)
Mar 2024$68.8 M
Jun 2024$120 M
Sep 2024$271 M
Dec 2024$240 M
Mar 2025$211 M
Apr 2025$211 M
Jun 2025$49.0 M
Sep 2025$290 M
Dec 2025$334 M
Mar 2026$252 M
Apr 2026$252 M
Jun 2026$308 M

Operating cash as % of profit

  • Operating cash as % of profit 145%
Operating cash as % of profit
QuarterOperating cash as % of profit
Mar 2024184%
Jun 202453%
Sep 2024230%
Dec 2024172%
Mar 2025132%
Apr 2025132%
Jun 202527%
Sep 2025150%
Dec 2025136%
Mar 2026120%
Apr 2026120%
Jun 2026145%
Top: operating cash each quarter, $ M. Below: operating cash as a % of net profit; 100% means all of the quarter's profit came in as cash. Last 12 quarters.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Where does Exelixis' cash go?

Exelixis, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $77.3 M on assets over the last 3 years. Averaged over those years that is 1.1% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $77.3 M over the last 3 years.

FY25: capex $8.4 M, down from the year before

  • Capex $8.4 M
FY25: capex $8.4 M, down from the year before
QuarterCapex
FY21$54.2 M
FY22$27.7 M
FY23$40.5 M
FY24$28.4 M
FY25$8.4 M
Capital spending each year, $ M.

Jun 2026: capex $6.8 M in the quarter

  • Capex (quarterly) $6.8 M
Jun 2026: capex $6.8 M in the quarter
QuarterCapex (quarterly)
Mar 2024$9.7 M
Jun 2024$6.6 M
Sep 2024$8.2 M
Dec 2024$4.0 M
Mar 2025$3.0 M
Apr 2025$3.0 M
Jun 2025$2.8 M
Sep 2025$1.5 M
Dec 2025$1.2 M
Mar 2026$1.5 M
Apr 2026$1.5 M
Jun 2026$6.8 M

Free cash

  • Free cash $301 M
Free cash
QuarterFree cash
Mar 2024$59.1 M
Jun 2024$113 M
Sep 2024$263 M
Dec 2024$236 M
Mar 2025$208 M
Apr 2025$208 M
Jun 2025$46.2 M
Sep 2025$289 M
Dec 2025$332 M
Mar 2026$250 M
Apr 2026$250 M
Jun 2026$301 M
Top: capital spending each quarter, $ M. Below: free cash flow, $ M. Last 12 quarters.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is Exelixis' P/E ratio, and how does it compare with its own history?

Exelixis, Inc.'s P/E is 21.7×, in the middle of its own history: higher than 54% of past readings. Its usual P/E (the middle reading) is 21.1×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

P/E 21.7× against a usual 21.1×: in the middle of its own history: higher than 54% of past readings

  • P/E 22.0×
  • Median 21.1×
P/E 21.7× against a usual 21.1×: in the middle of its own history: higher than 54% of past readings
WeekP/EMedian
1 Apr 202224.5×21.1×
14 Apr 202224.7×21.1×
29 Apr 202223.9×21.1×
13 May 202221.5×21.1×
27 May 202219.7×21.1×
10 Jun 202219.4×21.1×
24 Jun 202223.8×21.1×
8 Jul 202225.9×21.1×
22 Jul 202224.5×21.1×
5 Aug 202225.3×21.1×
19 Aug 202222.7×21.1×
2 Sep 202221.1×21.1×
16 Sep 202220.2×21.1×
30 Sep 202216.4×21.1×
14 Oct 202216.4×21.1×
28 Oct 202217.4×21.1×
11 Nov 202217.6×21.1×
25 Nov 202217.7×21.1×
9 Dec 202216.5×21.1×
23 Dec 202216.5×21.1×
6 Jan 202330.6×21.1×
20 Jan 202329.7×21.1×
3 Feb 202331.1×21.1×
17 Feb 202331.0×21.1×
3 Mar 202330.4×21.1×
17 Mar 202331.1×21.1×
31 Mar 202341.0×21.1×
14 Apr 202341.0×21.1×
28 Apr 202338.6×21.1×
12 May 202340.5×21.1×
26 May 202340.4×21.1×
9 Jun 202340.5×21.1×
23 Jun 202341.9×21.1×
7 Jul 202338.3×21.1×
21 Jul 202339.1×21.1×
4 Aug 202340.2×21.1×
18 Aug 202341.9×21.1×
1 Sep 202345.1×21.1×
15 Sep 202343.3×21.1×
29 Sep 202343.4×21.1×
13 Oct 202363.2×21.1×
27 Oct 202363.2×21.1×
10 Nov 202363.2×21.1×
24 Nov 202363.2×21.1×
8 Dec 202363.2×21.1×
22 Dec 202363.2×21.1×
5 Jan 202435.9×21.1×
19 Jan 202434.7×21.1×
2 Feb 202433.2×21.1×
16 Feb 202431.6×21.1×
1 Mar 202434.4×21.1×
15 Mar 202435.5×21.1×
28 Mar 202436.7×21.1×
12 Apr 202435.3×21.1×
26 Apr 202436.6×21.1×
10 May 202433.0×21.1×
24 May 202431.8×21.1×
7 Jun 202433.8×21.1×
21 Jun 202434.3×21.1×
5 Jul 202418.9×21.1×
19 Jul 202419.4×21.1×
2 Aug 202420.7×21.1×
16 Aug 202422.6×21.1×
30 Aug 202422.3×21.1×
13 Sep 202422.7×21.1×
27 Sep 202422.3×21.1×
11 Oct 202416.8×21.1×
25 Oct 202417.8×21.1×
8 Nov 202423.2×21.1×
22 Nov 202422.8×21.1×
6 Dec 202422.9×21.1×
20 Dec 202421.3×21.1×
3 Jan 202519.2×21.1×
17 Jan 202520.4×21.1×
31 Jan 202518.7×21.1×
14 Feb 202519.8×21.1×
28 Feb 202521.9×21.1×
14 Mar 202520.7×21.1×
28 Mar 202520.7×21.1×
11 Apr 202517.8×21.1×
25 Apr 202518.8×21.1×
9 May 202518.2×21.1×
23 May 202521.3×21.1×
6 Jun 202521.6×21.1×
20 Jun 202520.3×21.1×
3 Jul 202520.6×21.1×
18 Jul 202519.9×21.1×
1 Aug 202516.6×21.1×
15 Aug 202517.1×21.1×
29 Aug 202516.7×21.1×
12 Sep 202517.5×21.1×
26 Sep 202517.4×21.1×
10 Oct 202515.6×21.1×
24 Oct 202515.8×21.1×
7 Nov 202516.7×21.1×
21 Nov 202517.4×21.1×
5 Dec 202518.1×21.1×
19 Dec 202518.1×21.1×
2 Jan 202615.7×21.1×
16 Jan 202615.8×21.1×
30 Jan 202614.9×21.1×
13 Feb 202615.8×21.1×
27 Feb 202615.8×21.1×
13 Mar 202614.8×21.1×
27 Mar 202614.9×21.1×
10 Apr 202613.9×21.1×
24 Apr 202614.1×21.1×
8 May 202615.2×21.1×
22 May 202615.8×21.1×
5 Jun 202616.6×21.1×
18 Jun 202616.3×21.1×
2 Jul 202616.9×21.1×
17 Jul 202616.9×21.1×
31 Jul 202616.0×21.1×
14 Aug 202615.5×21.1×
28 Aug 202616.5×21.1×
11 Sep 202617.0×21.1×
25 Sep 202617.6×21.1×
9 Oct 202618.1×21.1×
23 Oct 202619.5×21.1×
4 Nov 202622.0×21.1×

Earnings per share, 12 months

  • Earnings per share, 12 months $3.31
Earnings per share, 12 months
WeekEarnings per share, 12 months
1 Apr 2022–
14 Apr 2022–
29 Apr 2022–
13 May 2022–
27 May 2022–
10 Jun 2022–
24 Jun 2022$0.94
8 Jul 2022$0.94
22 Jul 2022$0.94
5 Aug 2022$0.94
19 Aug 2022$0.94
2 Sep 2022$0.94
16 Sep 2022$0.94
30 Sep 2022$0.96
14 Oct 2022$0.96
28 Oct 2022$0.96
11 Nov 2022$0.96
25 Nov 2022$0.96
9 Dec 2022$0.96
23 Dec 2022$0.96
6 Jan 2023$0.96
20 Jan 2023$0.96
3 Feb 2023$0.96
17 Feb 2023$0.96
3 Mar 2023$0.96
17 Mar 2023$0.96
31 Mar 2023$0.47
14 Apr 2023$0.47
28 Apr 2023$0.47
12 May 2023$0.47
26 May 2023$0.47
9 Jun 2023$0.47
23 Jun 2023$0.50
7 Jul 2023$0.50
21 Jul 2023$0.50
4 Aug 2023$0.50
18 Aug 2023$0.50
1 Sep 2023$0.50
15 Sep 2023$0.50
29 Sep 2023$0.50
13 Oct 2023$0.50
27 Oct 2023$0.50
10 Nov 2023$0.50
24 Nov 2023$0.50
8 Dec 2023$0.50
22 Dec 2023$0.50
5 Jan 2024$0.28
19 Jan 2024$0.28
2 Feb 2024$0.28
16 Feb 2024$0.28
1 Mar 2024$0.28
15 Mar 2024$0.28
28 Mar 2024$0.65
12 Apr 2024$0.65
26 Apr 2024$0.65
10 May 2024$0.65
24 May 2024$0.65
7 Jun 2024$0.65
21 Jun 2024$0.65
5 Jul 2024$0.65
19 Jul 2024$0.65
2 Aug 2024$0.65
16 Aug 2024$0.65
30 Aug 2024$0.65
13 Sep 2024$0.65
27 Sep 2024$1.17
11 Oct 2024$1.17
25 Oct 2024$1.17
8 Nov 2024$1.17
22 Nov 2024$1.17
6 Dec 2024$1.17
20 Dec 2024$1.17
3 Jan 2025$1.56
17 Jan 2025$1.56
31 Jan 2025$1.56
14 Feb 2025$1.56
28 Feb 2025$1.56
14 Mar 2025$1.56
28 Mar 2025$1.77
11 Apr 2025$1.77
25 Apr 2025$1.77
9 May 2025$1.77
23 May 2025$1.77
6 Jun 2025$1.77
20 Jun 2025$1.77
3 Jul 2025$1.99
18 Jul 2025$1.99
1 Aug 2025$1.99
15 Aug 2025$1.99
29 Aug 2025$1.99
12 Sep 2025$1.99
26 Sep 2025$2.24
10 Oct 2025$2.24
24 Oct 2025$2.24
7 Nov 2025$2.24
21 Nov 2025$2.24
5 Dec 2025$2.24
19 Dec 2025$2.24
2 Jan 2026$2.45
16 Jan 2026$2.45
30 Jan 2026$2.45
13 Feb 2026$2.45
27 Feb 2026$2.45
13 Mar 2026$2.45
27 Mar 2026$2.78
10 Apr 2026$2.78
24 Apr 2026$2.78
8 May 2026$2.78
22 May 2026$2.78
5 Jun 2026$2.78
18 Jun 2026$2.78
2 Jul 2026$3.18
17 Jul 2026$3.18
31 Jul 2026$3.18
14 Aug 2026$3.18
28 Aug 2026$3.18
11 Sep 2026$3.18
25 Sep 2026$3.31
9 Oct 2026$3.31
23 Oct 2026$3.31
4 Nov 2026$3.31
Top: P/E each week. Below: earnings per share, trailing twelve months, a step line that moves once a quarter; 4.6 years of history; short peaks above 63× are drawn at the top edge.

PEG 1.51 at the Jun 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate

  • PEG 1.51×
  • PEG = 1.0 1.00×
PEG 1.51 at the Jun 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate
QuarterPEGPEG = 1.0
Sep 20210.71×1.00×
Dec 20211.05×1.00×
Mar 20220.74×1.00×
Jun 20220.61×1.00×
Sep 20220.46×1.00×
Dec 20220.83×1.00×
Mar 20231.00×1.00×
Jun 20230.80×1.00×
Sep 20231.18×1.00×
Dec 20230.89×1.00×
Mar 20240.62×1.00×
Jun 20240.54×1.00×
Sep 20240.70×1.00×
Dec 20240.50×1.00×
Mar 20251.10×1.00×
Apr 20251.10×1.00×
Jun 20250.79×1.00×
Sep 20250.70×1.00×
Dec 20250.53×1.00×
Mar 20261.39×1.00×
Apr 20261.39×1.00×
Jun 20261.51×1.00×
PEG each quarter: the P/E divided by the yearly growth rate of earnings. The flat line marks 1.0. Below it the P/E is smaller than the growth rate; above it the P/E is bigger. Last 22 quarters.
21.7×P/E · higher than 54% of its last 4.6 years
1.60PEG · today, as reported

Why the multiple is where it is: over the past year earnings per share moved +58.0% while the price moved +78.3%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +51.3% a year; about +127.8% a year came from earnings growth and about −76.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Is the Exelixis business getting better or worse?

Exelixis, Inc.'s business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 43.1%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Growth year by year: revenue +7.0% in FY25, profit +50.1%

  • Revenue growth 7.0%
Growth year by year: revenue +7.0% in FY25, profit +50.1%
QuarterRevenue growth
FY21–
FY2212.3%
FY2313.6%
FY2418.5%
FY257%

Profit growth, EPS growth

  • Profit growth 50.1%
  • EPS growth 58%
Profit growth, EPS growth
QuarterProfit growthEPS growth
FY21––
FY22−21.1%−22.2%
FY2314%16.1%
FY24150.9%170.8%
FY2550.1%58%
Growth on the year before, each year, %. Top: revenue. Below: net profit and earnings per share, on their own scale because profit growth swings much more. Zero line drawn.

Three growth lines over twelve quarters: revenue stabilising, profit rolling over

  • Revenue 7.6%
Three growth lines over twelve quarters: revenue stabilising, profit rolling over
QuarterRevenue
Mar 202411%
Jun 202417.5%
Sep 202417.3%
Dec 202418.5%
Mar 202524.5%
Apr 202510.1%
Jun 20257.9%
Sep 20255%
Dec 20250.9%
Mar 20267.1%
Apr 20267.7%
Jun 20267.6%

Profit, EPS

  • Profit 25.8%
  • EPS 35.2%
Profit, EPS
QuarterProfitEPS
Mar 202433.4%36.5%
Jun 2024113.1%131.6%
Sep 2024300%300%
Dec 2024150.9%173.6%
Mar 2025213.9%240%
Apr 202564.9%70.3%
Jun 202537.9%43.1%
Sep 202533.8%38.2%
Dec 202521.6%26.4%
Mar 202644.4%51.7%
Apr 202633.4%42%
Jun 202625.8%35.2%
Growth on a year earlier, % at each quarter end. Top: revenue. Below: profit and earnings per share, on their own scale because they swing much more. Each is measured over the last 12 months. Extreme jumps from a tiny base are drawn at the edge (▲). A gap means there is no reading for that quarter.

ROCE: the return line, worked out each quarter

  • ROCE 43.1%
ROCE: the return line, worked out each quarter
QuarterROCE
Mar 20247.8%
Jun 202415.4%
Sep 202423.5%
Dec 202427.1%
Mar 202533.5%
Apr 202529.8%
Jun 202530.6%
Sep 202533.8%
Dec 202536.6%
Mar 202641.1%
Apr 202643.6%
Jun 202643.1%
Operating profit over the last 12 months (before interest and tax) as a share of average capital employed (total assets minus current liabilities), %.
Steady highRevenue growth · latest +7.6%, range +0.9% to +24.5%
Steady highProfit growth · latest +25.8%, range +21.6% to +407.1%
Steady highEPS growth · latest +35.2%, range +26.4% to +458.7%
RisingROCE · latest 43.1%, range 7.8% to 43.6%

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+7.0%+12.9%——
Profit+50.1%+62.5%——
EPS+58.0%+70.6%——
Stock price+78.3%+51.3%+30.3%+19.8%
+10.6%Revenue growth (Jun 2026) · latest quarter against a year ago
+14.7%Profit growth (Jun 2026) · latest quarter against a year ago
12.8%Revenue, 4 years · yearly growth over the long run

How much does Exelixis earn on its capital?

Exelixis, Inc. earned a ROE of 36% in FY25. That is up from a low of 7% in FY22. Its return on capital used (ROIC) is 66.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 33.7% net margin and 0.82× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 33.7% net margin × 0.82× asset turnover × 1.32× leverage (assets divided by equity) ≈ 36.5% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 73.3% − 6.5% = +66.8 percentage points. The 6.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 73.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 56.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

FY25: ROE 36%, the climb back from FY22's 7%

  • ROE 36.2%
  • ROIC (annual) 56%
  • Cost of capital 6.5%
FY25: ROE 36%, the climb back from FY22's 7%
QuarterROEROIC (annual)Cost of capital
FY2110.5%29.5%6.5%
FY227.3%14.3%6.5%
FY239.2%9.6%6.5%
FY2423.2%37.2%6.5%
FY2536.2%56%6.5%
Return on equity each year, % (line); ROIC each year, % (line). 5-year window, low years included. The flat line is the 6.5% cost of capital used on this page.

Jun 2026: ROIC 61.6% (last 12 months) against a 6.5% cost of capital

  • ROIC (12 months) 61.6%
  • ROE (12 months) 41.1%
  • Cost of capital 6.5%
Jun 2026: ROIC 61.6% (last 12 months) against a 6.5% cost of capital
QuarterROIC (12 months)ROE (12 months)Cost of capital
Mar 202410.6%14.8%6.5%
Jun 202412.2%6.8%6.5%
Sep 202423.7%42.6%6.5%
Dec 202434.9%21.5%6.5%
Mar 202539.6%24.8%6.5%
Apr 202547.4%7.5%6.5%
Jun 202542.5%29.2%6.5%
Sep 202544.1%35.5%6.5%
Dec 202548.9%36.9%6.5%
Mar 202655%45.3%6.5%
Apr 202659.2%10.4%6.5%
Jun 202661.6%41.1%6.5%
ROIC and ROE over the last 12 months, each quarter, %; the flat line is the cost of capital. Last 12 quarters, lined up with the yearly figure.

Does Exelixis have too much debt?

Exelixis, Inc. has total debt of $166 M against shareholder equity of $1.8 B as of Jun 2026, so its debt is 0.09× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.09 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

FY25: debt $201 M, 0.09× equity

  • Total debt $201 M
FY25: debt $201 M, 0.09× equity
QuarterTotal debt
FY21$56.4 M
FY22$208 M
FY23$216 M
FY24$216 M
FY25$201 M

Debt-to-equity

  • Debt-to-equity 0.09×
Debt-to-equity
QuarterDebt-to-equity
FY210.03×
FY220.08×
FY230.10×
FY240.10×
FY250.09×
Top: total debt each year, $ M. Below: debt-to-equity, ×. 5-year window.

Jun 2026: debt $166 M, debt-to-equity 0.09

  • Total debt (quarterly) $166 M
Jun 2026: debt $166 M, debt-to-equity 0.09
QuarterTotal debt (quarterly)
Mar 2024$201 M
Jun 2024$198 M
Sep 2024$194 M
Dec 2024$216 M
Mar 2025$187 M
Apr 2025$187 M
Jun 2025$180 M
Sep 2025$176 M
Dec 2025$201 M
Mar 2026$170 M
Apr 2026$170 M
Jun 2026$166 M

Debt-to-equity

  • Debt-to-equity 0.09×
Debt-to-equity
QuarterDebt-to-equity
Mar 20240.09×
Jun 20240.09×
Sep 20240.09×
Dec 20240.10×
Mar 20250.09×
Apr 20250.09×
Jun 20250.09×
Sep 20250.08×
Dec 20250.09×
Mar 20260.09×
Apr 20260.09×
Jun 20260.09×
Top: total debt each quarter, $ M. Below: debt-to-equity, ×. Last 12 quarters.

What is the Exelixis shareholding pattern?

13.0% of Exelixis, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 11.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

13.0%Short interest · of the tradable float
11.7Days to cover · at typical volumes

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

How far is Exelixis from balance-sheet trouble?

For Exelixis, Inc., the Z-score is 13.36. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 13.36 is well clear of the danger zone, so the balance sheet is not the risk here.

How does Exelixis rank in its industry?

76.0 out of 100, rank 1 of 30 in Biotechnology, with 81% of the evidence available.

Exelixis, Inc. scores 76.0 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.

The four parts add up to the total exactly: 22.9 + 21 + 14.4 + 17.7 = 76. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Exelixis compared with?

Exelixis ranks 1 of 30 Biotechnology companies on the 4-Factor Sector Score, with 76.0 out of 100.

  1. 1Exelixis, Inc. this pageEXEL · breaking out · Most evidence points up · 81% evidence76.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.9/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidenceCapital efficiency 21.0/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidenceValuation 14.4/20 · P/E 15.9× · PEG 0.3 · 65% evidenceRelative strength 17.7/20 · Lead over its industry 10.5% · Lead over S&P 500 37% · 1 year 78.3% · 100% evidence · 8 of 12 weeks aheadExact sum: 22.9 + 21 + 14.4 + 17.7 = 76 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Halozyme Therapeutics, Inc.HALO · leader · Most evidence points up · 81% evidence71.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.1/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidenceCapital efficiency 21.0/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidenceValuation 14.4/20 · P/E 22.4× · PEG 0.25 · 65% evidenceRelative strength 18.6/20 · Lead over its industry 22.6% · Lead over S&P 500 50.7% · 1 year 91% · 100% evidence · 12 of 12 weeks aheadExact sum: 17.1 + 21 + 14.4 + 18.6 = 71.1 · What this means: Relative strength against the index is 50.7%, and revenue and profit growth are weak.
  3. 3Caris Life Sciences, Inc.CAI · leader · Most evidence points up · 64% evidence65.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.7/35 · Revenue 85.4% · Profit — · Operating margin change 20.1 points · 62% evidenceCapital efficiency 13.1/25 · ROCE 14.8% · Operating margin 10.2% · 76% evidenceValuation 11.2/20 · P/E -14.2× · PEG — · 15% evidenceRelative strength 17.7/20 · Lead over its industry 10.2% · Lead over S&P 500 37.4% · 1 year 29.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 23.7 + 13.1 + 11.2 + 17.7 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Incyte CorporationINCY · turning · Evidence leans up · 71% evidence64.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.4/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidenceCapital efficiency 20.6/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidenceValuation 10.7/20 · P/E 14× · PEG — · 15% evidenceRelative strength 6.6/20 · Lead over its industry -13.6% · Lead over S&P 500 7.7% · 1 year 15.9% · 100% evidence · 5 of 12 weeks aheadExact sum: 26.4 + 20.6 + 10.7 + 6.6 = 64.3 · What this means: Earnings are strong; relative strength in its sector is -13.6% and the one-year return is 15.9%.
  5. 5Genmab A/SGMAB · leader · Evidence leans up · 81% evidence60.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 10.7/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidenceCapital efficiency 15.7/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidenceValuation 14.9/20 · P/E 21.4× · PEG 0.21 · 65% evidenceRelative strength 19.5/20 · Lead over its industry 32.8% · Lead over S&P 500 65.2% · 1 year 92.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 10.7 + 15.7 + 14.9 + 19.5 = 60.8 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak.
  6. 6argenx SEARGX · turning · Evidence leans up · 85% evidence58.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.7/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidenceCapital efficiency 16.9/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidenceValuation 9.8/20 · P/E 32× · PEG 1.39 · 65% evidenceRelative strength 7.4/20 · Lead over its industry -18.3% · Lead over S&P 500 2.3% · 1 year 9% · 100% evidence · 6 of 12 weeks aheadExact sum: 24.7 + 16.9 + 9.8 + 7.4 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Kymera Therapeutics, Inc.KYMR · turning · Evidence leans up · 61% evidence57.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.7/35 · Revenue 100% · Profit — · Operating margin change 620.5 points · 62% evidenceCapital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidenceValuation 10.0/20 · P/E — · PEG — · 0% evidenceRelative strength 17.1/20 · Lead over its industry 12.3% · Lead over S&P 500 38.4% · 1 year 132.3% · 100% evidence · 7 of 12 weeks aheadExact sum: 23.7 + 6.8 + 10 + 17.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Vertex Pharmaceuticals IncorporatedVRTX · breaking out · Evidence leans up · 81% evidence56.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.9/35 · Revenue 10.2% · Profit 21.1% · Operating margin change -0.8 points · 83% evidenceCapital efficiency 19.6/25 · ROCE 20.9% · Operating margin 38.1% · 76% evidenceValuation 10.9/20 · P/E 28.6× · PEG 1.25 · 65% evidenceRelative strength 9.7/20 · Lead over its industry -13% · Lead over S&P 500 8.5% · 1 year 34.1% · 100% evidence · 8 of 12 weeks aheadExact sum: 15.9 + 19.6 + 10.9 + 9.7 = 56.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Spyre Therapeutics, Inc.SYRE · quiet · Too little evidence to rank firmly · 56% evidence55.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.3/35 · Revenue — · Profit — · Operating margin change 999.3 points · 52% evidenceCapital efficiency 8.6/25 · ROCE -24.5% · Operating margin — · 61% evidenceValuation 10.9/20 · P/E -8.2× · PEG — · 15% evidenceRelative strength 13.0/20 · Lead over its industry 18.5% · Lead over S&P 500 43.8% · 1 year 339.8% · 100% evidence · 4 of 12 weeks aheadExact sum: 23.3 + 8.6 + 10.9 + 13 = 55.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  10. 10BeOne Medicines AGONC · leader · Evidence leans up · 64% evidence54.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.3/35 · Revenue 34.3% · Profit — · Operating margin change 12.4 points · 62% evidenceCapital efficiency 13.4/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidenceValuation 9.1/20 · P/E 48.3× · PEG — · 15% evidenceRelative strength 10.1/20 · Lead over its industry -13.3% · Lead over S&P 500 8.4% · 1 year 17.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 22.3 + 13.4 + 9.1 + 10.1 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Moderna, Inc.MRNA · leader · Evidence leans up · 64% evidence54.7out of 100GrowthCapitalValuationRelative
  12. 12Jazz Pharmaceuticals plcJAZZ · quiet · Evidence leans up · 74% evidence53.6out of 100GrowthCapitalValuationRelative
  13. 13Regeneron Pharmaceuticals, Inc.REGN · leader · Evidence leans up · 81% evidence51.9out of 100GrowthCapitalValuationRelative
  14. 14Alnylam Pharmaceuticals, Inc.ALNY · quiet · Evidence leans up · 64% evidence51.1out of 100GrowthCapitalValuationRelative
  15. 15Royalty Pharma plcRPRX · turning · Evidence leans up · 81% evidence50.9out of 100GrowthCapitalValuationRelative
  16. 16ImmunityBio, Inc.IBRX · breaking out · Evidence leans down · 61% evidence49.5out of 100GrowthCapitalValuationRelative
  17. 17Protagonist Therapeutics, Inc.PTGX · losing its lead · Evidence leans down · 74% evidence49.2out of 100GrowthCapitalValuationRelative
  18. 18Bio-Techne CorporationTECH · turning · Evidence leans down · 74% evidence42.2out of 100GrowthCapitalValuationRelative
  19. 19Summit Therapeutics Inc.SMMT · breaking out · Too little evidence to rank firmly · 53% evidence39.7out of 100GrowthCapitalValuationRelative
  20. 20Revolution Medicines, Inc.RVMD · quiet · Too little evidence to rank firmly · 53% evidence39.5out of 100GrowthCapitalValuationRelative
  21. 21Roivant Sciences Ltd.ROIV · turning · Too little evidence to rank firmly · 60% evidence38.0out of 100GrowthCapitalValuationRelative
  22. 22Madrigal Pharmaceuticals, Inc.MDGL · quiet · Evidence leans down · 61% evidence36.4out of 100GrowthCapitalValuationRelative
  23. 23Insmed IncorporatedINSM · basing · Evidence leans down · 61% evidence35.2out of 100GrowthCapitalValuationRelative
  24. 24BridgeBio Pharma, Inc.BBIO · quiet · Most evidence points down · 61% evidence34.8out of 100GrowthCapitalValuationRelative
  25. 25BioNTech SEBNTX · quiet · Most evidence points down · 64% evidence32.4out of 100GrowthCapitalValuationRelative
  26. 26BioMarin Pharmaceutical Inc.BMRN · quiet · Most evidence points down · 81% evidence26.7out of 100GrowthCapitalValuationRelative
  27. 27Ascendis Pharma A/SASND · turning · Too little evidence to rank firmly · 44% evidence63.0out of 100GrowthCapitalValuationRelative
  28. 28Apogee Therapeutics, Inc.APGE · Too little evidence to rank firmly · 27% evidence46.7out of 100GrowthCapitalValuationRelative
  29. 29Nuvalent, Inc.NUVL · Too little evidence to rank firmly · 20% evidence40.9out of 100GrowthCapitalValuationRelative
  30. 30Vaxcyte, Inc.PCVX · breaking out · Too little evidence to rank firmly · 47% evidence38.2out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Biotechnology, all 30 compared on one page.

Which companies are close to Exelixis in size?

Exelixis is the 14th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Insmed Incorporated, BioNTech SE and Alnylam Pharmaceuticals, Inc. Just below it: Ascendis Pharma A/S, BridgeBio Pharma, Inc. and Jazz Pharmaceuticals plc.

Biotechnology companies close in size

  1. Insmed Incorporated $24.1 billion
  2. BioNTech SE $22.5 billion
  3. Alnylam Pharmaceuticals, Inc. $21.6 billion
  4. Exelixis, Inc. $17.8 billion
  5. Ascendis Pharma A/S $16.9 billion
  6. BridgeBio Pharma, Inc. $15.2 billion
  7. Jazz Pharmaceuticals plc $15.1 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

  1. Hyatt Hotels Corporation $17.8 billion · Lodging
  2. YPF Sociedad Anónima $17.8 billion · Oil & Gas Integrated
  3. Exelixis, Inc. $17.8 billion
  4. Brookfield Infrastructure Partners L.P. $17.7 billion · Utilities - Diversified
  5. RB Global, Inc. $17.6 billion · Specialty Business Services

What else do people ask about Exelixis?

What were Exelixis's latest quarterly results?

Exelixis, Inc. reported revenue of $629 M and net profit of $212 M for the Jun 2026 quarter. Revenue rose 10.6% and profit rose 14.7% compared with a year earlier. Earnings per share were $0.82.

The operating margin was 39.5%, 1.9 percentage points higher than a year earlier (as of 4 November 2026).

What is Exelixis's market cap?

Exelixis, Inc.'s market capitalisation is $17.8 B at a stock price of $72.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026).

How is Exelixis performing?

Exelixis, Inc.'s share price has been rising for 32 weeks. In its latest quarter, revenue rose 10.6% and profit rose 14.7% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 12 weeks running (as of 4 November 2026).

Will Exelixis's stock price go up?

This page does not forecast Exelixis, Inc.'s stock price. What it shows instead: the stock price is $72.75, and it has been rising for 32 weeks. Its P/E of 21.7× is higher than 54% of its own last 5 years (as of 4 November 2026).

Where is Exelixis in its business cycle?

Exelixis, Inc.'s FY25 operating margin was 38.5%, against a 5-year range of 9.3% to 38.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 39.5%.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026).

What could break the Exelixis story?

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026).

Is Exelixis a stock worth studying right now?

What the numbers show: Exelixis, Inc. is reporting record margins. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.